Cargando…

Correction to: Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy

Detalles Bibliográficos
Autores principales: Ritter, Violetta, Krautter, Franziska, Klein, Diana, Jendrossek, Verena, Rudner, Justine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9018877/
https://www.ncbi.nlm.nih.gov/pubmed/35440079
http://dx.doi.org/10.1038/s41419-022-04743-7
_version_ 1784689127177846784
author Ritter, Violetta
Krautter, Franziska
Klein, Diana
Jendrossek, Verena
Rudner, Justine
author_facet Ritter, Violetta
Krautter, Franziska
Klein, Diana
Jendrossek, Verena
Rudner, Justine
author_sort Ritter, Violetta
collection PubMed
description
format Online
Article
Text
id pubmed-9018877
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-90188772022-04-28 Correction to: Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy Ritter, Violetta Krautter, Franziska Klein, Diana Jendrossek, Verena Rudner, Justine Cell Death Dis Correction Nature Publishing Group UK 2022-04-19 /pmc/articles/PMC9018877/ /pubmed/35440079 http://dx.doi.org/10.1038/s41419-022-04743-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Correction
Ritter, Violetta
Krautter, Franziska
Klein, Diana
Jendrossek, Verena
Rudner, Justine
Correction to: Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy
title Correction to: Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy
title_full Correction to: Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy
title_fullStr Correction to: Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy
title_full_unstemmed Correction to: Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy
title_short Correction to: Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy
title_sort correction to: bcl-2/bcl-xl inhibitor abt-263 overcomes hypoxia-driven radioresistence and improves radiotherapy
topic Correction
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9018877/
https://www.ncbi.nlm.nih.gov/pubmed/35440079
http://dx.doi.org/10.1038/s41419-022-04743-7
work_keys_str_mv AT rittervioletta correctiontobcl2bclxlinhibitorabt263overcomeshypoxiadrivenradioresistenceandimprovesradiotherapy
AT krautterfranziska correctiontobcl2bclxlinhibitorabt263overcomeshypoxiadrivenradioresistenceandimprovesradiotherapy
AT kleindiana correctiontobcl2bclxlinhibitorabt263overcomeshypoxiadrivenradioresistenceandimprovesradiotherapy
AT jendrossekverena correctiontobcl2bclxlinhibitorabt263overcomeshypoxiadrivenradioresistenceandimprovesradiotherapy
AT rudnerjustine correctiontobcl2bclxlinhibitorabt263overcomeshypoxiadrivenradioresistenceandimprovesradiotherapy